ѻý

<ѻý class="page-title">Meeting Coverage

EHA

<ѻý class="page-description">European Hematology Association
Glofitamab Regimen Improves Survival in DLBCL

Granted accelerated approval last year, bispecific antibody passes its confirmatory test

EHA over a photo of IFEMA Madrid in Spain.
<ѻý class="section_title">Latest EHA Meeting Coverage
Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Undetectable MRD rates of 90% or higher, PFS of 7 years or more

June 17, 2024
New Standard of Care in High-Risk Acute Promyelocytic Leukemia?

All-trans retinoic acid plus arsenic trioxide and idarubicin improved EFS over standard

June 17, 2024
Atezolizumab Consolidation Impresses in High-Risk DLBCL

Will 2-year DFS of 88%, OS of 96% renew interest in checkpoint inhibitor consolidation?

June 14, 2024
Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphoma

ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment

June 21, 2022
Fixed-Duration, All-Oral Regimen Slows CLL Progression

Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil

June 16, 2021
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma

Better response rates and survival with axicabtagene ciloleucel versus external control group

June 15, 2021
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL

Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor

June 14, 2021
Combination Ups Survival in Older AML Patients

Frontline venetoclax plus azacitidine adds 5 months to median OS versus azacitidine alone

June 17, 2020
Biologic Effective in Light Chain Amyloidosis

Anti-CD38 therapy added to conventional regimen boosts PFS in trial

June 16, 2020
Keytruda Tops Adcetris in Head-to-Head Hodgkin's Trial

Checkpoint inhibitor improved PFS in refractory and transplant-ineligible cases

June 15, 2020
New Standard for Relapsed/Refractory Multiple Myeloma?

Triplet regimen significantly extended median PFS versus doublet in IKEMA study

June 15, 2020
FLT3-ITD Inhibitor Improves Survival in Relapsed AML

More quizartinib-treated patients went on to stem cell transplant

June 19, 2018
Lymphoma Risk with JAK Inhibitors for MPNs

Preexisting aberrant B-cell clone implicated

June 18, 2018
One Proteasome Inhibitor Tops Another in Relapsed Myeloma

Progression-free survival doubled with carfilzomib versus bortezomib

June 15, 2015